These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 22683237)

  • 1. Disruption of spine homeostasis causes dopaminergic compensatory up-regulation, resulting in schizophrenia.
    Sato K
    Med Hypotheses; 2012 Sep; 79(3):304-7. PubMed ID: 22683237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of spine homeostasis causes depression.
    Sato K
    Med Hypotheses; 2013 Jul; 81(1):5-9. PubMed ID: 23631853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopaminergic mechanisms in the pathogenesis of schizophrenia.
    Goldstein M; Deutch AY
    FASEB J; 1992 Apr; 6(7):2413-21. PubMed ID: 1348713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The n-3 polyunsaturated fatty acid/dopamine hypothesis of schizophrenia.
    Ohara K
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):469-74. PubMed ID: 17184889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs.
    Lidow MS; Elsworth JD; Goldman-Rakic PS
    J Pharmacol Exp Ther; 1997 Apr; 281(1):597-603. PubMed ID: 9103549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neurodevelopment and schizophrenia].
    De Erausquin GA
    Vertex; 2002; 13(49):189-97. PubMed ID: 12404020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New perspectives on biological treatment of schizophrenia.
    Lingjaerde O
    Acta Psychiatr Scand Suppl; 1994; 384():102-7. PubMed ID: 7879631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality.
    Svensson TH
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1145-58. PubMed ID: 14642973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The n-3 fatty acid/dopamine hypothesis in schizophrenia].
    Ohara K
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2006 Aug; 26(4):149-53. PubMed ID: 17020131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
    Nikam SS; Awasthi AK
    Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired neuronal glucose uptake in pathogenesis of schizophrenia - can GLUT 1 and GLUT 3 deficits explain imaging, post-mortem and pharmacological findings?
    McDermott E; de Silva P
    Med Hypotheses; 2005; 65(6):1076-81. PubMed ID: 16125330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia.
    Bencherif M; Stachowiak MK; Kucinski AJ; Lippiello PM
    Med Hypotheses; 2012 May; 78(5):594-600. PubMed ID: 22336089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.
    Okubo Y; Suhara T; Suzuki K; Kobayashi K; Inoue O; Terasaki O; Someya Y; Sassa T; Sudo Y; Matsushima E; Iyo M; Tateno Y; Toru M
    Nature; 1997 Feb; 385(6617):634-6. PubMed ID: 9024661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A biochemical theory of schizophrenia].
    Kornhuber HH; Kornhuber J; Kim JS; Kornhuber ME
    Nervenarzt; 1984 Nov; 55(11):602-6. PubMed ID: 6151120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment.
    Remington G; Agid O; Foussias G
    Expert Rev Neurother; 2011 Apr; 11(4):589-607. PubMed ID: 21469931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
    Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Schizophrenia and addiction: An evaluation of the self-medication hypothesis].
    Potvin S; Stip E; Roy JY
    Encephale; 2003; 29(3 Pt 1):193-203. PubMed ID: 12876543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholinergic aspects of schizophrenia.
    Tandon R
    Br J Psychiatry Suppl; 1999; (37):7-11. PubMed ID: 10211133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.